Abstract 344P
Background
Acute myeloid leukemia (AML) is primarily treated with chemotherapy. Patients who are unable to undergo intensive chemotherapy may receive substitutional therapy, such as venetoclax, a BCL-2 inhibitor that showed promising results by combining it with azacitidine. Recent clinical trials have demonstrated the effectiveness of venetoclax-azacitidine in AML treatment. Thus, this review aims to compare the efficacy and serious adverse events (SAE) of venetoclax-azacitidine vs azacitidine used alone in patients diagnosed with AML.
Methods
Authors independently extracted studies from 2013 to 2023 using databases such as Pubmed, Pubmed Central, Springer Link, ScienceDirect, Medrxiv, and Google Scholar. Keywords used were "venetoclax" AND "azacitidine" AND "acute myeloid leukemia". We assessed the quality of each study using the modified JADAD scale with funnel plot to assess publication bias and Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) to determine the quality of this review. A pooled analysis of OS and EFS hazard ratio (HR) and SAE ratio between the two groups were done to establish correlation.
Results
We included 7 records, representing 3 trials, involving 1499 patients. 2 studies were of low quality, with the other 3 studies and the other 2 studies were of moderate and high quality respectively. This review showed moderate quality based on GRADE with minimum publication bias. The use of combining venetoclax and azacitidine did improve OS (HR = 0.58; 95% CI 0.51-0.65 ; P < 0.001) and EFS (HR = 0.50 ; 95% CI 0.30-0.84 ; P = 0.008), but have higher SAE (OR = 1.81 ; 95% CI 1.29-2.52 ; P = 0.0005) compared to azacitidine alone.
Conclusions
This review revealed that venetoclax-azacitidine demonstrated enhanced OS and EFS outcomes, with higher serious adverse events (SAE) when compared to azacitidine in AML patients. This concludes that venetoclax-azacitidine holds promise as a potential treatment for AML patients although its safety still needs to be monitored closely. Further studies needed to observe the administration of venetoclax-azacitidine vs azacitidine AML in different subgroups, more importantly the cytogenetic risk.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
26P - Subcutaneous trastuzumab versus intravenous trastuzumab for treatment of patients with HER2-positive breast cancer: A time, motion and cost-benefit assessment in a day care oncology unit in China
Presenter: Bei Sun
Session: Poster Display
Resources:
Abstract
27P - The biological characteristics of HER2-low in TNBC using mRNA profiling and molecular subtypes
Presenter: Asako Tsuruga
Session: Poster Display
Resources:
Abstract
28P - One-week ultra-hypofractionated partial breast RT in early breast cancer: 3DCRT vs IMRT
Presenter: Nurilla Zaynutdinov
Session: Poster Display
Resources:
Abstract
30P - Stereotactic body radiotherapy using cyberknife versus interstitial brachytherapy in accelerated partial breast irradiation on left-sided breast: A comparison of preliminary clinical result and dosimetric characteristics
Presenter: Ting-Na Wei
Session: Poster Display
Resources:
Abstract
31P - Prognostic implication of breast edema on preoperative breast MRI in breast cancer
Presenter: Ki-tae Hwang
Session: Poster Display
Resources:
Abstract
32P - Efficacy of olanzapine in the prophylaxis of delayed chemotherapy-induced nausea and vomiting in breast cancer patients receiving dose-dense AC with a steroid-sparing regimen: A single-center pilot study
Presenter: Manami Tada
Session: Poster Display
Resources:
Abstract
34P - Social support as the mediator of the association between unmet needs and happiness among women with early breast cancer
Presenter: Nithiya Sinarajoo
Session: Poster Display
Resources:
Abstract
35P - Prospective study assessing the efficacy and safety of a scalp cooling device for the prevention of alopecia in breast cancer patients undergoing (neo)adjuvant chemotherapy
Presenter: Winnie Yeo
Session: Poster Display
Resources:
Abstract
37P - To excise or not to excise: Preventive management of early breast cancer in atypical ductal hyperplasia patients
Presenter: Clarisse Hing
Session: Poster Display
Resources:
Abstract
38P - Exploring prognostic factors in patients achieving PCR after neoadjuvant therapy for triple-negative breast cancer: A retrospective study based on SEER data
Presenter: Lv Wenjie
Session: Poster Display
Resources:
Abstract